Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial

By afschroeder • July 23, 2026

Chandran S, Tang Q, Leung JC, Armstrong BD, Friedewald JJ, Kirk AD, Laszik ZG, Goldstein J, Morsheimer M, Vincenti FG. Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial. Am J Transplant. 2026 Jul 22:S1600-6135(26)02676-6. doi: 10.1016/j.ajt.2026.07.016. Epub ahead of print. PMID: 42486389.

Tags: belatacept, Cedars Sinai DoM, Clinical Trial, costimulation blockade, Interleukin-6, kidney transplantation, lulizumab, Nephrology, Publications, regulatory T cells, Tocilizumab

Related Posts

Use of Myocardial Perfusion Imaging to Guide Prognosis and Management in Older Adults: Is There an Age Limit?

Patel KK, Miller RJH, Lemley M, Shanbhag A, Ramirez G, Liang JX, Acampa W, Bateman TM, Dorbala S, Einstein AJ, Hauser MT, Kaufmann PA, Feher[...]

Bioactive Lipids of Cardiorespiratory Fitness Insights From Exercise Models in Humans, Mice, and Burmese Pythons

Guseh JS, Roshandelpoor A, Alotaibi M, Zarbafian S, Lau ES, Kuznetsov A, Rosenzweig A, Saeidi N, Choudhary A, Jain M, Cheng S, Lewis GD, Ho[...]

Improved plaque composition from intensive medical treatment in women with angina and non-obstructive coronary disease

Lenell J, Flores Tomasino G, Han D, Wolny R, Park C, Grodecki K, Kwiecinski J, Xing E, Manral N, Asebiomo F, Goyal D, Calsavara VF,[...]